Emgality

Emgality (galcanezumab) is a prescription medication used to prevent migraines. This subcutaneous injection is manufactured by Eli Lilly Nederland B.V. and is designed to help reduce the frequency of migraine episodes.

Emgaleity is primarily used for the prevention of migraines in adults. It is not intended for the acute treatment of migraines once they have started. The medication works by targeting a protein involved in the pathogenesis of migraines, helping to reduce the number of migraine days experienced by patients.

Common effects of Emgality may include injection site reactions such as pain, redness, or swelling. Some users may also experience constipation, fatigue, or upper respiratory infections. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare provider.

Emgality should be used with caution in individuals with a history of severe hypersensitivity reactions to galcanezumab or any of its components. It is important to inform your healthcare provider about all medical conditions and medications you are taking before starting Emgality. The medication should be stored at room temperature and protected from light.

Emgality may interact with other medications, including those that affect the immune system or blood pressure. It is important to discuss all current medications with your healthcare provider to avoid potential interactions. Alcohol consumption should be moderated, as it may exacerbate some side effects.